$3,000.00
Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how
they may influence the market and future deal-making.
Overview
Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how
they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae
portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds. Amidst market turbulence, companies
will continue their search for mid-sized pipeline-centric growth assets, given increasing cash balances and uncertain revenue
projections. Will M&A continue to remain an appetizing strategic policy to fuel further consolidation?
PharmaVitae Portfolio
Analysis structure
Explore and visualize M&A dynamics in the pharmaceutical and biotechnology industries:
executive summary
deal trend analysis
major deal discussion
looking ahead
potential targets
Key questions answered
Explore and assess recent deals based on deal size and company type
How is the industry using M&A as a vehicle to propel a strategy for growth?
Delve deeper into the largest deals of 2015
What’s the outlook for M&A in 2016?
What companies are still out on the prowl for M&A deals?
What companies constitute the most likely targets?
Highlights
$437bn worth of deals has been completed in 2015 for pharmaceutical and biotechnology companies.
Biggest deal: Pfizer’s $160bn deal terminated deal Allergan would have been biggest deal in the industry’s history
Biggest spenders: Companies in Datamonitor Healthcare’s PharmaVitae portfolio were involved in $385bn worth of deals
Portfolio transformation: Companies continue to explore asset stripping
Targeted deal-making: Companies continue to gain a larger foothold in therapeutic areas of strength
Tax-inversions: Tax-inversions have spilt over in 2015
2016 Outlook: Pipeline-centric acquisitions will continue to bolster companies that have remained largely passive
About the PharmaVitae Team
Datamonitor Healthcare’s PharmaVitae team tracks and forecasts the performance of the top 35 pharmaceutical and biotechnology
companies operating in the global prescription pharmaceutical market.
For more information about the PharmaVitae Team, please contact Ali Al-Bazergan, Lead Analyst: ali.al-bazergan@informa.com
About the data
Deal information was sourced from MedTrack, in which dates refer to completion rather than announced
Deals by segments refer to the type of company being acquired irrespective to the industry of the acquirer.
Figure 1: 2008 and 2012 M&A Cycle by year and quarter – Pharmaceutical and Biotechnology deals
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!